Lake Street analyst Thomas Flaten raised the firm’s price target on Personalis (PSNL) to $11 from $9 and keeps a Buy rating on the shares after the company reported Q3 revenue ahead of the guided range, the firm’s estimate and consensus. While noting that Personalis lowered 2025 revenue guidance to reflect macro headwinds in the biopharma business, the firm argues that the key driver of future revenue growth and share price appreciation will be reimbursement.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL: